101 related articles for article (PubMed ID: 26520626)
1. Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
Tarighi P; Khorramizadeh M; Madadkar-Sobhani A; Ostad S; Ghahremani M
Acta Med Iran; 2015 Jul; 53(7):403-7. PubMed ID: 26520626
[TBL] [Abstract][Full Text] [Related]
2. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
3. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.
Mani T; Wang F; Knabe WE; Sinn AL; Khanna M; Jo I; Sandusky GE; Sledge GW; Jones DR; Khanna R; Pollok KE; Meroueh SO
Bioorg Med Chem; 2013 Apr; 21(7):2145-55. PubMed ID: 23411397
[TBL] [Abstract][Full Text] [Related]
5. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
Guo Y; Higazi AA; Arakelian A; Sachais BS; Cines D; Goldfarb RH; Jones TR; Kwaan H; Mazar AP; Rabbani SA
FASEB J; 2000 Jul; 14(10):1400-10. PubMed ID: 10877833
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for therapeutic intervention of uPA/uPAR system.
Ngo JC; Jiang L; Lin Z; Yuan C; Chen Z; Zhang X; Yu H; Wang J; Lin L; Huang M
Curr Drug Targets; 2011 Nov; 12(12):1729-43. PubMed ID: 21707478
[TBL] [Abstract][Full Text] [Related]
7. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
9. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator system as a potential target for cancer therapy.
Mekkawy AH; Morris DL; Pourgholami MH
Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells.
Ahmad A; Kong D; Wang Z; Sarkar SH; Banerjee S; Sarkar FH
J Cell Biochem; 2009 Nov; 108(4):916-25. PubMed ID: 19693769
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
Liu D; Overbey D; Watkinson L; Giblin MF
Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
[TBL] [Abstract][Full Text] [Related]
13. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
15. Modulators of the urokinase-type plasminogen activation system for cancer.
Hildenbrand R; Allgayer H; Marx A; Stroebel P
Expert Opin Investig Drugs; 2010 May; 19(5):641-52. PubMed ID: 20402599
[TBL] [Abstract][Full Text] [Related]
16. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
18. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
[TBL] [Abstract][Full Text] [Related]
19. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
20. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
